STOCK TITAN

Lucid Diagnostics Inc. - LUCD STOCK NEWS

Welcome to our dedicated page for Lucid Diagnostics news (Ticker: LUCD), a resource for investors and traders seeking the latest updates and insights on Lucid Diagnostics stock.

Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage medical diagnostics company dedicated to cancer prevention, particularly focusing on patients with gastroesophageal reflux disease (GERD). GERD, commonly known as chronic heartburn or acid reflux, places millions at risk of developing esophageal precancer and the highly lethal esophageal adenocarcinoma. Lucid's groundbreaking products, EsoCheck and EsoGuard, are at the forefront of early detection and prevention.

EsoGuard is a bisulfite-converted Next Generation Sequencing (NGS) DNA assay performed on surface esophageal cells collected with the EsoCheck device. This test quantifies methylation at 31 sites on two genes, Vimentin (VIM) and Cyclin A1 (CCNA1), detecting esophageal precancer and cancer with over 90% sensitivity and specificity. EsoCheck is an FDA 510(k) and CE Mark cleared noninvasive swallowable balloon capsule catheter device. This device can sample surface esophageal cells in less than five minutes, providing an effective, non-invasive alternative to costly and invasive endoscopy.

Lucid has shown substantial progress, including solid revenue growth on stable test volumes. Their revenue cycle management processes are improving, and the CYFT program targeting specific groups like firefighters is thriving. Their direct contracting initiative is also accelerating, with near-term prospects for delivering contracts, testing, and revenue.

Recently, Lucid announced a partnership with the Esophageal Cancer Action Network (ECAN) to highlight Esophageal Cancer Awareness Month. Public service videos run on Nasdaq's billboard in Times Square, spreading awareness about the link between heartburn and esophageal cancer.

Lucid's peer-reviewed publication of positive data from a National Cancer Institute (NCI)-sponsored study confirmed the high sensitivity and specificity of the EsoGuard test. This significant milestone supports their goal of widespread screening and early detection, moving towards Medicare coverage.

Lucid continues to advance its operations and strategies, recently closing a $30 million preferred stock financing to support their growth. They are on track to achieve key milestones, including expanded private and public coverage and direct contracting. Lucid's clinical evidence base for EsoGuard is robust, further enhancing their line of sight to Medicare coverage.

For more information, visit www.luciddx.com and their parent company PAVmed at www.pavmed.com.

Rhea-AI Summary
PAVmed and Lucid Diagnostics to participate in Cantor Fitzgerald Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
conferences
-
Rhea-AI Summary
PAVmed and Lucid Diagnostics to participate in Cantor Fitzgerald Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
conferences
-
Rhea-AI Summary
Lucid Diagnostics Inc. has released positive interim data from the multicenter CLUE study, demonstrating the real-world clinical utility of EsoGuard Esophageal DNA testing. The study shows excellent concordance between test results and subsequent medical decision-making by multiple physicians.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
none
Rhea-AI Summary
Lucid Diagnostics announces positive data from a study demonstrating clinical utility of EsoGuard® Esophageal DNA testing in fire fighters
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.88%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
none
Rhea-AI Summary
PAVmed Inc., a diversified medical technology company, will host a business update conference call and webcast on May 17, 2023, at 8:30 AM EST. The call will provide a business update and overview of operations and growth strategy by the Chairman and CEO, Lishan Aklog, M.D. The President and CFO, Dennis McGrath, will discuss the first-quarter 2023 financial results. The webcast will be available on the company's website, and a replay will be available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.35%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.35%
Tags
none
-
Rhea-AI Summary

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) has appointed Gary Manning as the President of its majority-owned subsidiary, Veris Health. Manning brings over 30 years of digital health and medical technology experience, which includes expertise in developing innovative solutions for patient care. His role will focus on driving the commercialization of the Veris Cancer Care Platform™ and guiding product development and regulatory milestones for an implantable cardiac monitor. Chairman and CEO Lishan Aklog expressed confidence in Manning's ability to enhance Veris’s strategic direction. The Veris Cancer Care Platform enables remote monitoring of cancer patients, integrating Bluetooth-enabled devices to transmit health data. This appointment is anticipated to strengthen Veris's market position in personalized cancer care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.27%
Tags
management
Rhea-AI Summary

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) presented a meta-analysis on Remote Patient Monitoring (RPM) at the HIMSS23 Global Health Conference on April 19, 2023. This analysis, titled "RPM for Oncology: Bringing the Hospital Home to Improve Lives," highlights RPM's potential to enhance quality of care, reduce healthcare costs, and improve patient experiences. The meta-analysis reviewed nearly two decades of oncology research from over ten countries, emphasizing the integration of RPM with patient-reported outcomes (ePROs) for personalized cancer care. PAVmed's digital health subsidiary, Veris Health, showcased its Veris Cancer Care Platform™ during the session, which enables remote monitoring and real-time data transmission to improve patient management.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.84%
Tags
conferences

FAQ

What is the current stock price of Lucid Diagnostics (LUCD)?

The current stock price of Lucid Diagnostics (LUCD) is $0.781 as of December 20, 2024.

What is the market cap of Lucid Diagnostics (LUCD)?

The market cap of Lucid Diagnostics (LUCD) is approximately 46.9M.

What is Lucid Diagnostics Inc.?

Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage medical diagnostics company focused on cancer prevention, particularly for patients with gastroesophageal reflux disease (GERD).

What are EsoCheck and EsoGuard?

EsoCheck is a noninvasive device for collecting esophageal cells, and EsoGuard is a DNA assay test performed on these cells to detect esophageal precancer and cancer.

Why are GERD patients at risk?

GERD can lead to esophageal precancer and cancer, specifically esophageal adenocarcinoma, which is highly lethal if not detected early.

How does EsoGuard work?

EsoGuard quantifies DNA methylation at specific sites to detect esophageal precancer and cancer with high sensitivity and specificity.

What recent achievements has Lucid Diagnostics announced?

Lucid announced partnerships, positive clinical study results, and financial growth, including a $30 million preferred stock financing.

What partnerships has Lucid Diagnostics formed?

Lucid partnered with the Esophageal Cancer Action Network (ECAN) to increase awareness about the links between heartburn and esophageal cancer.

What are the financial highlights for Lucid Diagnostics?

Lucid has shown solid revenue growth, improved revenue cycle management, and successful execution of their commercial strategy.

What is the significance of the NCI-sponsored study?

The study validated EsoGuard's high sensitivity and specificity, marking a significant step towards widespread screening and Medicare coverage.

How does Lucid's technology compare to traditional methods?

Lucid's technology offers a non-invasive alternative to endoscopy, making it more accessible and cost-effective for early detection of esophageal precancer.

What are Lucid's future plans?

Lucid aims to expand private and public coverage, secure Medicare coverage for EsoGuard, and continue their commercial growth and partnerships.

Lucid Diagnostics Inc.

Nasdaq:LUCD

LUCD Rankings

LUCD Stock Data

46.87M
23.24M
59.09%
4.18%
0.53%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
NEW YORK